Results 11 to 20 of about 1,187,996 (336)

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.

open access: yesThe Lancet, 2021
BACKGROUND First-line chemotherapy for advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma has a median overall survival (OS) of less than 1 year.
Y. Janjigian   +28 more
semanticscholar   +1 more source

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial

open access: yesNature Medicine, 2023
In the randomized, double-blind, phase 3 GLOW trial, capecitabine and oxaliplatin combined with zolbetuximab, a monoclonal antibody that targets CLDN18.2, significantly improved progression-free survival and overall survival in patients with CLDN18.2 ...
M. Shah   +20 more
semanticscholar   +1 more source

Lung adenocarcinoma promotion by air pollutants

open access: yesNature, 2023
A complete understanding of how exposure to environmental substances promotes cancer formation is lacking. More than 70 years ago, tumorigenesis was proposed to occur in a two-step process: an initiating step that induces mutations in healthy cells ...
William Hill   +326 more
semanticscholar   +1 more source

Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

open access: yesThe Journal of the National Comprehensive Cancer Network, 2021
Pancreatic cancer is the fourth leading cause of cancer-related death among men and women in the United States. A major challenge in treatment remains patients' advanced disease at diagnosis.
M. Tempero   +35 more
semanticscholar   +1 more source

Proteogenomic characterization of pancreatic ductal adenocarcinoma.

open access: yesCell, 2021
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient survival. Toward understanding the underlying molecular alterations that drive PDAC oncogenesis, we conducted comprehensive proteogenomic analysis of 140 pancreatic ...
L. Cao   +138 more
semanticscholar   +1 more source

Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD)

open access: yesBiomedicines, 2023
Objective: The RNA-binding protein RBM10 can regulate apoptosis during the proliferation and migration of pancreatic cancer, endometrial cancer, and osteosarcoma cells; however, the molecular mechanism underlying lung adenocarcinoma is rarely reported ...
Liusheng Wu   +7 more
semanticscholar   +1 more source

Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma

open access: yesNature Communications, 2020
Advanced metastatic cancer poses utmost clinical challenges and may present molecular and cellular features distinct from an early-stage cancer. Herein, we present single-cell transcriptome profiling of metastatic lung adenocarcinoma, the most prevalent ...
N. Kim   +20 more
semanticscholar   +1 more source

Comprehensive molecular profiling of lung adenocarcinoma

open access: yesNature, 2014
Adenocarcinoma of the lung is the leading cause of cancer death worldwide. Here we report molecular profiling of 230 resected lung adenocarcinomas using messenger RNA, microRNA and DNA sequencing integrated with copy number, methylation and proteomic ...
Eric A. Joshua D. Angela N. Alice H. William Juliann Da Collisson Campbell Brooks Berger Lee Chmielecki Be   +356 more
semanticscholar   +1 more source

Metachronous Intraductal Papillary Neoplasm of the Bile Duct and Intraductal Papillary Mucinous Neoplasm of the Pancreas in a Patient Diagnosed With Mucinous Adenocarcinoma. [PDF]

open access: yes, 2019
Intraductal papillary neoplasm of the bile duct (IPNB) is a rare biliary tumor, which shares some radiologic and histologic similarities with pancreatic intraductal papillary mucinous neoplasm (IPMN).
Brennan, Gregory T, Lee, John G
core   +1 more source

Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma.

open access: yesCell, 2020
To explore the biology of lung adenocarcinoma (LUAD) and identify new therapeutic opportunities, we performed comprehensive proteogenomic characterization of 110 tumors and 101 matched normal adjacent tissues (NATs) incorporating genomics, epigenomics ...
Michael A. Gillette   +24 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy